UNSPSC 51321713: Atorvastatin strontium

This classification denotes a hmg-coa reductase inhibitor 2C33H34FN2O5.Sr, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier AMJ4WWI6NM, chemically known as h-pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)-.beta.,.delta.-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-, strontium salt (2:1), (.beta.r,.delta.r)-, but more generally known as atorvastatin strontium, which bears US NIH Compound Identifier 24875347. Most nations, for tariff and trade purposes, schedule atorvastatin strontium under HS 29339990 and SITC 51577.

As of Q4 2014, ATORVASTATIN STRONTIUM remains US FDA's Preferred Term for this commodity. SMILES: CC(C)C1C(C(C(N1CC[C@H](C[C@H](CC(=O)[O-])O)O)C2CCC(CC2)F)C3CCCCC3)C(=O)NC4CCCCC4.CC(C)C1C(C(C(N1CC[C@H](C[C@H](CC(=O)[O-])O)O)C2CCC(CC2)F)C3CCCCC3)C(=O)NC4CCCCC4.[SR+2].

UNSPSC 51321713 Atorvastatin strontium is a Commodity code covering a specific pharmaceutical active ingredient used in cardiovascular medications that state and local governments procure through fire rescue services, health agencies, and cooperative purchasing vehicles. Recent solicitations under this code show that state and local buyers are acquiring medications for emergency medical services and pharmacy benefit programs through sealed-bid procurements, requests for information, and multistate cooperative purchasing agreements. The Tampa Fire Rescue solicitation exemplifies the operational scope: state and local emergency response organizations purchase specific medications in unit quantities with strict expiration-date requirements, warranty terms, and delivery windows measured in days. Beyond emergency services, state health agencies and cooperative purchasing alliances are seeking manufacturers and distributors to supply pharmaceutical products including generics through authorized wholesalers, with pricing tied to National Drug Codes and compliance certifications in cGMP and the Drug Supply Chain Security Act. Issuing bodies span city purchasing departments (Tampa), state health commissions (Texas HHS), and multistate cooperative alliances (MMCAP administered by Minnesota Department of Administration), reflecting a mix of direct municipal procurement and collaborative state-level contracting.

Recent activity concentrates in Florida, Texas, and the upper Midwest (Minnesota and Oregon participating in MMCAP). The City of Tampa's Purchasing Department issued an IFB for Advanced Life Support Medications (Solicitation 26P00188, due April 8, 2026) valued at $40,000.00, requesting four medication line items for Tampa Fire Rescue with nine-month minimum expiration dates and ten-day delivery, using a Small Local Business Enterprise sheltered market with a 5 percent bid discount. The Texas Health and Human Services Commission issued RFI HHS0017013 (posted April 3, 2026) to explore direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager arrangements, signaling potential future procurement expansion. MMCAP's RFP (S1070000015802, due March 26, 2026) sought generic multi-source pharmaceutical manufacturers to supply through three authorized wholesalers, with July 1, 2026 contract effective date and a two-year initial term, requiring vendors to maintain $5,000,000 commercial general liability and demonstrate pricing flexibility across multiple formats. No specific award value was disclosed for the MMCAP procurement, though a 3 percent administrative fee applies to all purchases.